OncoMatch/Clinical Trials/NCT03048084
Seizure Treatment in Glioma
Is NCT03048084 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Levetiracetam and Valproic Acid for glioma.
Treatment: Levetiracetam · Valproic Acid — Currently, treatment with a specific anti-epileptic drug mainly depends on the physicians' preference, as there are no studies supporting the use of one specific anticonvulsant in glioma patients. The overall aim of this randomized controlled trial is to directly compare the effectiveness of treatment with levetiracetam or valproic acid in glioma patients with a first seizure.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: 1P co-deleted
1p/19q co-deleted
Required: 19Q co-deleted
1p/19q co-deleted
Allowed: IDH1 wild-type
IDH-1 wildtype
Allowed: IDH1 mutated
IDH-1 mutated
Prior therapy
Cannot have received: antiepileptic drugs
Exception: emergency treatment in the past 2 weeks
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify